- PROMOTEÑо¿ÊÇÈ«ÇòÊ׸öÕë¶ÔALTˮƽÕý³£µÄÂýÐÔHBV¸ÐȾÕßµÄÇ°Õ°ÐÔ¡¢¶àÖÐÐÄ¡¢Ëæ»ú¶ÔÕÕÑо¿£¬ÎªALTÕý³£µÄÂýÐÔHBV¸ÐȾÈËȺÊÇ·ñÐèÒª¿¹²¡¶¾ÖÎÁÆÌṩÁËÑϽ÷µÄ¿Æѧ֤¾Ý¡£
- ±¾´ÎJCTH·¢±íµÄPROMOTEÑо¿48Öܽá¹û±íÃ÷£ººããå?ÔÚÖÎÁÆALTÕý³£µÄÂýÐÔHBV¸ÐȾÕßÖÐÈ¡µÃÁËÏÔÖøÁÆЧ£¬ÇÒ¾ßÓÐÁ¼ºÃµÄ¹Ç÷À¡¢ÉöÔàºÍѪ֬°²È«ÐÔ[1]¡£
- PROMOTEÑо¿Îª½üÄêÀ´¸Î²¡Ñ§½ç³«µ¼µÄÂýÐÔÒҸΡ°À©´óÖÎÁÆ¡±ÉõÖÁ¡°È«ÖΡ±£¨Treat All£©²ßÂÔÌṩÁËÖØÒªµÄÁÙ´²Ö¤¾ÝÖ§³Ö£¬¶ÔÓÚ¼õÇáÉç»á¼°»¼Õß¼²²¡¸ºµ£ÓÐ×ÅÖØÒªÒâÒå¡£
½üÈÕ£¬¸Î²¡ÁìÓòȨÍþÔÓÖ¾¡¶ÁÙ´²Óëת»¯¸ÎÔಡѧÔÓÖ¾¡·£¨Journal of Clinical and Translational Hepatology£©·¢±íÁËÒ»ÏîÆÀ¹ÀµÏÍþÖƵÏÍþ¹ú¼Ê×ÔÖ÷Ñз¢µÄÖйúÊ׸öÔÑпڷþ¿¹ÒÒÐ͸ÎÑײ¡¶¾µÏÍþ¹ú¼ÊÎïºããå?µÄPROMOTEÑо¿48ÖÜ·ÖÎö½á¹û¡£
Ñо¿½á¹û±íÃ÷£¬¼´Ê¹¶ÔÓÚALTÕý³£µÄÂýÐÔÒҸλ¼Õߣ¬²ÉÓÃÓÐЧµÄ¿¹²¡¶¾ÖÎÁÆ£¨Èçºããå?£©Ò²ÄÜÏÔÖøÒÖÖƲ¡¶¾¸´ÖÆ£¬¸ÄÉƸÎÔàÑ×Ö¢±êÖ¾Î½µµÍALTˮƽ¼°¡°Õý³£¸ßÖµ¡±ALT±ÈÀý£©£¬²¢¿ÉÄܽµµÍ¼²²¡½øÕ¹·çÏÕ£¬Í¬Ê±¾ßÓÐÁ¼ºÃµÄ¹Ç÷À¡¢ÉöÔàºÍѪ֬°²È«ÐÔ¡£
´«Í³¹ÛµãÈÏΪ£¬µ±ÂýÒҸλ¼Õß³öÏÖALTÉý¸ßʱ£¬²ÅÌáʾ¸ÎÔàÑ×Ö¢»î¶¯²¢Æô¶¯¿¹²¡¶¾ÖÎÁÆ¡£È»¶øÔ½À´Ô½¶àÖ¤¾Ý±íÃ÷£¬ÔÚÂýÒҸλ¼ÕßȺÌåÖУ¬ALTˮƽÕý³£µÄ»¼ÕßÒ²¿ÉÄÜ´æÔÚÏÔÖøµÄ¸ÎÔಡÀí¸Ä±ä£¬°üÀ¨¸ÎÏËά»¯ÉõÖÁ¸Îϸ°û°©£¨HCC£©·çÏÕ¡£Õë¶ÔÕâÒ»ÖØÒªµ«³£±»ºöÊÓµÄÈËȺ£¬PROMOTEÑо¿ÆÀ¹ÀÁ˺ããå?ÔÚALTÕý³£ÂýÐÔÒҸλ¼ÕßÖеÄÁÆЧÓ밲ȫÐÔ¡£
PROMOTEÑо¿£¨NCT05797714£©ÊÇÊ׸öÕë¶ÔALTˮƽÕý³££¨ALT£¼40 IU/L£©µÄÂýÐÔHBV¸ÐȾÕßµÄÇ°Õ°ÐÔ¡¢¶àÖÐÐÄ¡¢Ëæ»ú¡¢¿ª·Å±êÇ©¡¢¿Õ°×¶ÔÕÕÁÙ´²ÊÔÑ飬¹²ÓÐ12¼ÒҽѧÖÐÐIJÎÓë¡£
Èë×黼ÕßËæ»ú·ÖΪÁ½×飺ÖÎÁÆ×飨n=95£©¿Ú·þTMF 25mg£¬Ã¿ÈÕÒ»´Î£¬¼Æ»®³ÖÐøÖÎÁÆ144ÖÜ£»¶ÔÕÕ×飨n=102£©²»½ÓÊÜ¿¹²¡¶¾ÖÎÁÆ£¬½öËæ·Ã¹Û²ìÖÁ144ÖÜ¡£PROMOTEÑо¿48Öܽá¹ûÏÔʾ£º
¡ñ TMFÏÔÖøÒÖÖƲ¡¶¾¸´ÖÆ
ÔÚÖ÷ÒªÖÕµã·ÖÎöÖУ¨FAS¼¯£©£¬TMF×é48ÖÜʱ´ïµ½ÍêÈ«²¡¶¾Ñ§Ó¦´ð£¨HBV DNA < 20 IU/mL£©µÄ»¼Õß±ÈÀý¸ß´ï74.2%£¬¶ø¶ÔÕÕ×é½öΪ9.0%£¨P < 0.001£©¡£¼´Ê¹ÔÚδ´ïµ½ÍêÈ«²¡¶¾Ñ§Ó¦´ðµÄTMF×黼ÕßÖУ¬´ó¶àÊý»¼Õß²¡¶¾ÔØÁ¿½µÖÁ20-2000 IU/mLµÄµÍˮƽ¡£¶ø¶ÔÕÕ×éÓг¬¹ýÒ»°ë£¨53%£©µÄ»¼ÕßHBV DNA > 2000 IU/mL¡£
´ËÍ⣬TMF×é¹Û²ìµ½1ÀýHBsAgÏûʧ¼°ÑªÇåѧת»»²¡Àý£¬¶ÔÕÕ×éδ¹Û²ìµ½´ËÀàѪÇåѧ¸ÄÉÆ¡£HBsAgˮƽÔÚTMF×éµÄ½µ·ùÒ²ÏÔÖø´óÓÚ¶ÔÕÕ×飨-0.07 vs -0.04 log10 IU/mL£¬P=0.02£©¡£
¡ñ TMF¸ÄÉƸÎÔàÑ×֢״̬
TMF×黼ÕßµÄALTˮƽ×ÔÖÎÁƺóÓÐËùϽµ£¬²¢ÔÚ48ÖÜÄÚ³ÖÐøά³ÖÔڽϵÍˮƽ¡£Ïà±È¶ÔÕÕ×飬TMF×éALT½Ï»ùÏߵİٷֱȽµ·ùÏÔÖø¸ü´ó£¨-14.09%vs0%£¬ P=0.003£©¡£TMFÖÎÁÆ»¹ÏÔÖø½µµÍÁËALT¡°Õý³£¸ßÖµ¡±£¨20-40 IU/L£©µÄ»¼Õß±ÈÀý£¨´Ó»ùÏß60.9%½µÖÁ48ÖÜ46.2%£©£¬Ê¹¸ü¶à»¼ÕßµÄALTˮƽ½µÖÁ¸ü°²È«µÄ¡°µÍÕý³£¡±·¶Î§£¨¡Ü20 IU/L£©¡£
Ïà±È֮ϣ¬¶ÔÕÕ×éÓÐ7Àý»¼Õߣ¨7.0%£©³öÏÖÁË·ûºÏ¼²²¡½øÕ¹±ê×¼µÄALTÖèÉý£¨ALT Flare£¬¶¨ÒåΪALT > 2¡ÁULN£©£¬¶ø²»µÃ²»ÌáǰתÓÃTMFÖÎÁÆ£¬Í¹ÏÔÁËδÖÎÁÆ»¼ÕßDZÔڵļ²²¡»î¶¯·çÏÕ£¨P=0.014£©¡£TMF×éÔòÎÞ´ËÀàʼþ·¢Éú¡£
¡ñ ¹ÇÉö°²È«ÐÔÁ¼ºÃ£¬ÇÒ¶ÔѪ֬ÎÞ²»Á¼Ó°Ïì
°²È«ÐÔ·½Ã棬TMF×éÓë¶ÔÕÕ×éÔÚ48ÖÜʱµÄѪ¼¡ôû¡¢¹ÀËãÉöСÇòÂ˹ýÂÊ£¨eGFR£©¡¢ÑªÇåÁ×ÒÔ¼°¹Çת»»±êÖ¾Î¦Â-CTx, P1NP£©µÄ±ä»¯¾ùÎÞÏÔÖø²îÒ죨ËùÓÐP > 0.05£©£¬ÌáʾTMFµÄÉöÔà/¹Ç÷À°²È«ÐÔÁ¼ºÃ¡£TMF×éµÄ×ܵ¨¹Ì´¼¡¢¸ÊÓÍÈýõ¥¡¢µÍÃܶÈÖ¬µ°°×£¨LDL£©¡¢¸ßÃܶÈÖ¬µ°°×£¨HDL£©µÈÖ¸±êµÄ±ä»¯Óë¶ÔÕÕ×éÏà±ÈÒàÎÞÏÔÖø²îÒ죨ËùÓÐP > 0.05£©£¬ÌáʾTMF¶ÔѪ֬Æ×ÎÞ²»Á¼Ó°Ïì¡£
TMF×ÜÌåÄÍÊÜÐÔÁ¼ºÃ¡£´ó¶àÊýÖÎÁÆÖгöÏֵIJ»Á¼Ê¼þ£¨TEAE£©ÎªÇá¶È¡£TMF×é¡Ý3¼¶TEAE·¢ÉúÂʽöΪ2.1%£¬½ö1Àý»¼ÕßÒò²»Á¼Ê¼þÍ£µÏÍþ¹ú¼Ê¡£ÎÞËÀÍö²¡Àý±¨¸æ¡£
Ñо¿Õß»¹½«½øÒ»²½Íƽø¹ØÓÚºããå?96ÖܺÍ144Öܵij¤ÆÚÁÆЧ£¨°üÀ¨HBsAgϽµ¡¢HBeAgѪÇåѧת»»£©¡¢³¤ÆÚ°²È«ÐÔÒÔ¼°HBeAgÑôÐÔ»¼Õß³ÖÐøÖÎÁÆ»ñÒæµÄÑо¿¹Û²ì£¬ÕâЩ½á¹û¶ÔÓÚÓÅ»¯ÂýÐÔÒҸιÜÀí²ßÂÔ£¬ÌرðÊÇÃ÷È·ALTÕý³£ÈËȺµÄÖÎÁƼÛÖµºÍʱ»ú£¬¾ßÓÐÖØÒªÒâÒå¡£
²Î¿¼ÎÄÏ×£º
[1]Gui
H, Shen Y, Tan L, Hu P, Qian F, Wu X, et al. Interim Analysis of
48-week Tenofovir Amibufenamide Treatment in Chronic Hepatitis B
Patients with Normal Alanine Aminotransferase Levels: The PROMOTE Study.
J Clin Transl Hepatol. Published online: Jun 30, 2025. doi:
10.14218/JCTH.2025.00162.
µÏÍþÖƵÏÍþ¹ú¼ÊÊÇÖйúÁìÏȵĴ´ÐÂÇý¶¯ÐÍÖƵÏÍþ¹ú¼ÊÆóÒµ£¬ÒÔ¡¸³ÖÐø´´Ð£¬Ìá¸ßÈËÀàÉúÃüÖÊÁ¿¡¹ÎªÊ¹Ãü£¬Öصã¹Ø×¢¿¹Ö×Áö¡¢¿¹¸ÐȾ¡¢ÖÐÊàÉñ¾ÏµÍ³¡¢´úл¼°×ÔÉíÃâÒßµÈÖØ´ó¼²²¡ÖÎÁÆÁìÓò¡£½ØÖÁÄ¿Ç°£¬¹«Ë¾ÒÑÉÏÊÐ7¿î´´ÐµÏÍþ¹ú¼Ê£¬ÐγÉÁ˷ḻµÄ²úÆ·¹ÜÏß¡£µÏÍþÖƵÏÍþ¹ú¼ÊÁ¬Ðø¶àÄêλ¾ÓÈ«ÇòÖƵÏÍþ¹ú¼ÊÆóÒµ°ÙÇ¿¡¢ÖйúÒ½µÏÍþ¹ú¼ÊÑз¢²úÆ·Ïß×î¼Ñ¹¤ÒµÆóҵǰ3Ç¿£¬Êǹú¼ÒÖصã¸ßм¼ÊõÆóÒµ¡¢¹ú¼Ò¼¼Êõ´´ÐÂʾ·¶ÆóÒµ¡£µÏÍþÖƵÏÍþ¹ú¼ÊÓÚ2019Äê6ÔÂÔÚÏã¸ÛÁª½»Ëù¹ÒÅÆÉÏÊУ¨¹ÉƱ´úÂ룺03692.HK£©¡£¸ü¶àÐÅÏ¢Çë·ÃÎÊ£º/¡£
±¾ÎĽö¹©Ò½ÁÆÎÀÉúרҵÈËÊ¿²ÎÔÄ£¬·Ç¹ã¸æÓÃ;¡£µÏÍþÖƵÏÍþ¹ú¼Ê²»ÍƼöÈκÎδ»ñÅúµÏÍþ¹ú¼ÊƷʹÓúÍ/»òδ»ñÅúÊÊÓ¦Ö¢ÓõÏÍþ¹ú¼Ê£¬Ò಻¶ÔÈκεÏÍþ¹ú¼ÊÆ·ºÍ/»òÊÊÓ¦Ö¢×÷ÍƼö¡£±¾¹«¸æÖÐÉæ¼°µÄÐÅÏ¢½ö¹©²Î¿¼£¬Çë×ñ´ÓÒ½Éú»òÆäËûÒ½ÁÆÎÀÉúרҵÈËÊ¿µÄÒâ¼û»òÖ¸µ¼¡£Ò½ÁÆÎÀÉúרҵÈËÊ¿×÷³öµÄÈκÎÓëÖÎÁÆÓйصľö¶¨Ó¦¸ù¾Ý»¼ÕߵľßÌåÇé¿ö²¢×ñÕÕµÏÍþ¹ú¼ÊƷ˵Ã÷Êé¡£ÈçÐèÁ˽⹫˾ÈκβúÆ·¡¢Ò½ÁÆ»ò¼²²¡µÄÏà¹ØÐÅÏ¢£¬ÇëÎñ±Ø×ÉѯҽÁÆÎÀÉúרҵÈËÊ¿¡£
±¾ÐÂΟåÖ¼ÔÚÌṩ¹ØÓÚµÏÍþÖƵÏÍþ¹ú¼Ê¼¯ÍÅÓÐÏÞ¹«Ë¾¼°Æ丽Êô¹«Ë¾£¨°üÀ¨Æä×Ó¹«Ë¾£¬Í³³ÆΪ¡°µÏÍþÖƵÏÍþ¹ú¼Ê¡±£©µÄÐÅÏ¢¡£Ëü²»¹¹³É¶ÔµÏÍþÖƵÏÍþ¹ú¼Ê»òÈκÎͶ×ʽ¨ÒéµÄÐÅÏ¢Åû¶¡£
±¾ÐÂΟå°üº¬µÄÐÅÏ¢¿ÉÄÜ°üÀ¨ÓëµÏÍþÖƵÏÍþ¹ú¼ÊÒµÎñºÍ²úÆ·Ç°¾°¡¢¼Æ»®¡¢ÐÅÄî¡¢Ô¤ÆںͲßÂÔÏà¹ØµÄÇ°Õ°ÐÔÉùÃ÷¡£ÕâЩÉùÃ÷ÊÇ»ùÓÚÍƲâÐÔ¼ÙÉèµÄÔ¤²â£¬²¢²»±£Ö¤Î´À´µÄ±íÏÖ¡£ËüÃÇÊܵ½ÖîÈç¿Æѧ¡¢ÉÌÒµ¡¢ÕþÖΡ¢¾¼Ã¡¢²ÆÎñ¡¢·¨ÂÉÒòËØÒÔ¼°¾ºÕù»·¾³ºÍÉç»áÌõ¼þµÈ·çÏպͲ»È·¶¨ÐÔµÄÓ°Ï죬ÕâЩÒòËغܶ඼ÊǵÏÍþÖƵÏÍþ¹ú¼ÊÎÞ·¨¿ØÖÆÇÒÄÑÒÔÔ¤²âµÄ£¬Òò´Ëʵ¼Ê½á¹û¿ÉÄÜÓë´Ë´¦ËùÊöÓÐÏÔÖø²îÒ죬ÇÒ¹ýÈ¥µÄ֤ȯ¼Û¸ñÇ÷ÊƲ»Ó¦×÷ΪδÀ´ÐÐÇéµÄÖ¸µ¼¡£Òò´Ë£¬Í¶×ÊÕßÔÚʹÓÃÕâЩÐÅÏ¢½øÐÐͶ×ʾö²ßʱӦ½÷É÷ÐÐÊ¡£¡°ÖÂÁ¦ÓÚ¡±¡°Ô¤ÆÚ¡±¡°ÏàÐÅ¡±¡°Ô¤²â¡±¡°Òâͼ¡±¡°Ô¤¼Æ¡±¡°¿ÉÄÜ¡±¡°½«¡±¡°Ó¦¸Ã¡±¡°¼Æ»®¡±¡°¼ÌÐø¡±¡°Ä¿±ê¡±¡°¿¼ÂÇ¡±¡°¹À¼Æ¡±¡°Ö¸µ¼¡±¡°Ç±ÔÚ¡±¡°×·Çó¡±ÒÔ¼°ÓÚÈκÎδÀ´¼Æ»®¡¢Ðж¯»òʼþµÄÌÖÂÛÖÐʹÓõÄÀàËÆ´ÊÓïºÍÊõÓ¾ù±íʾǰհÐÔÉùÃ÷¡£
µÏÍþÖƵÏÍþ¹ú¼Ê²»³Ðŵ»ò±£Ö¤Ç°Õ°ÐÔÐÅÏ¢µÄ׼ȷÐÔ¡¢¼°Ê±ÐÔ»òÍêÕûÐÔ£¬²¢ÇÒ²»³Ðµ£¸üлòÐÞ¶©ÕâЩǰհÐÔÉùÃ÷µÄÒåÎñ¡£ÎÞÂÛÊǵÏÍþÖƵÏÍþ¹ú¼Ê»¹ÊÇÆäÈκζÊ¡¢Ô±¹¤»ò´úÀíÈË£¬¾ù²»¶ÔÈκÎÖ¤Ã÷²»×¼È·»òÎÞ·¨ÊµÏÖµÄÇ°Õ°ÐÔÉùÃ÷¸ºÔð£¬Ò²²»¶ÔÒòÒÀÀµ±¾ÐÂΟåÖÐÌṩµÄÐÅÏ¢¶ø²úÉúµÄÈκÎËðʧ»òË𺦸ºÔ𣬰üÀ¨µ«²»ÏÞÓÚÖ±½Ó¡¢Å¼È»¡¢¼ä½Ó»ò³Í·£ÐÔµÄË𺦡£
¼ò
¤™
